BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16967042)

  • 1. Effects of highly active antiretroviral therapy and immune recovery on CD8+ T-cell-mediated inhibition of HIV-1 transcription.
    Beaudoin G; Diker B; Angel JB; Copeland KF
    J Acquir Immune Defic Syndr; 2006 Dec; 43(4):393-400. PubMed ID: 16967042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naive CD4+ T lymphocytes express high levels of Bcl-2 after highly active antiretroviral therapy for HIV infection.
    Airò P; Torti C; Uccelli MC; Malacarne F; Palvarini L; Carosi G; Castelli F
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1805-7. PubMed ID: 11118066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
    Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription.
    Mackewicz CE; Blackbourn DJ; Levy JA
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2308-12. PubMed ID: 7534418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
    Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
    AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
    Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
    AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.
    Chang TL; Mosoian A; Pine R; Klotman ME; Moore JP
    J Virol; 2002 Jan; 76(2):569-81. PubMed ID: 11752148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T cell supernatants of HIV type 1-infected individuals have opposite effects on long terminal repeat-mediated transcription in T cells and monocytes.
    Copeland KF; Leith JG; McKay PJ; Rosenthal KL
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):71-7. PubMed ID: 8989429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.
    Chang TL; François F; Mosoian A; Klotman ME
    J Virol; 2003 Jun; 77(12):6777-84. PubMed ID: 12767998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
    Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
    Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
    J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.